Sort   by:  
 Page size 
UnknownA Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.
Not available
S-EPMC5315079 | biostudies-literature
UnknownKeynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer.
Not available
S-EPMC7791256 | biostudies-literature
UnknownBeyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets.
Not available
S-EPMC6381014 | biostudies-literature
UnknownDrug Development in Tissue-Agnostic Indications.
Not available
S-EPMC8199632 | biostudies-literature
UnknownParadigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Not available
S-EPMC8197177 | biostudies-literature
UnknownCore variables for real-world clinicogenomic data collection in precision oncology.
Not available
S-EPMC12836595 | biostudies-literature
UnknownRisks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis.
Not available
S-EPMC8548931 | biostudies-literature
UnknownHDAC Inhibition to Prime Immune Checkpoint Inhibitors.
Not available
S-EPMC8750966 | biostudies-literature
UnknownInternal validation strategy for high dimensional prognosis model: A simulation study and application to transcriptomic in head and neck tumors.
Not available
S-EPMC12451366 | biostudies-literature
UnknownPlasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors.
Not available
S-EPMC9762837 | biostudies-literature
Sort   by:  
 Page size